Table 1. Summary of data on efficacy and safety of targeted agents in metastatic NSCLC.

^ahttp://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.

^bPatient population was not selected for EGFR‐sensitizing mutations.

^cSamples can be formalin‐fixed, paraffin‐embedded tissue, or plasma ctDNA.

^dGrade 1/2 events are listed if they occurred in ≥20%; all grade ≥3 are listed.

^eNot associated with an approved test.

Abbreviations: AE, adverse event; ALK, anaplastic lymphoma kinase gene; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BICR, blinded independent review committee; BRAF, B‐Raf proto‐oncogene; CI, confidence interval; ctDNA, circulating tumor; DoR, duration of response; EGFR, epidermal growth factor receptor; FDA, U.S. Food and Drug Administration; HER2, human epidermal growth factor receptor 2 gene; HR, hazard ratio; IA, investigator assessment; ILD, interstitial lung disease; IRC, independent review committee; IRR, independent radiology review; MET, mesenchymal‐epithelial transition gene; mDoR, median duration of response; NE, not estimable; NR, not reached; NSCLC, non‐small cell lung cancer; ORR: objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression‐free survival; qd, once a day; RET, ret proto‐oncogene; ROS1, reactive oxygen species proto‐oncogene 1; TKI, tyrosine kinase inhibitor; TRAE, treatment‐related adverse event.